Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: StockDung who wrote (64401)	12/14/2000 11:39:01 AM
From: Land Shark	Read Replies (1) \| Respond to of 122087

Come on baby take out that support @ 52 1/4

To: StockDung who wrote (64401)	12/14/2000 12:48:30 PM
From: Oleg Sogolov	Read Replies (1) \| Respond to of 122087

Here is a PR that I found hilarious: Thursday December 14, 12:16 pm Eastern Time Press Release SOURCE: Utah Medical Products, Inc. Utah Medical Products Projects Financial Results for Fourth Quarter 2000 And Year 2001 SALT LAKE CITY, Dec. 14 /PRNewswire/ -- Because of the current prevalence of earnings warnings from other companies and its lack of independent investment firm research analyst coverage, Utah Medical Products, Inc. (Nasdaq: UTMD - news) projects its best estimate of earnings per share (eps) for year 2000 including current fourth quarter results, and year 2001, looking forward. Calendar Year, ending DEC: 1998 1999 2000 2001 Actual Actual Projected Projected Diluted Earnings Per Share: $ .587 $ .760 $ .90 $1.10 EPS Increase over prior year: +15.4% +29.4% +19% +22% Despite lower sales activity in 2000 compared to 1999, UTMD expects its operating profits to be higher due to higher gross profit margins and tightly controlled operating expenses. The excellent increase in eps results from the effect of a 17% decrease in diluted shares used to calculate eps. In 2001, UTMD will again benefit from about a 16% decrease in diluted shares, depending on the share price at the time earnings are reported, as a result of its repurchase of shares in the September 2000 tender offer. In addition, UTMD expects to increase both sales activity and net profits about 6% as a result of new products introduced in 4Q 2000 and improved distribution of its existing core products. ``If I were a stock analyst, I would point out that if UTMD's P/E ratio were anything close to its 22% eps growth rate, the stock should be trading around $20 per share,'' states CEO Kevin Cornwell. ``The current average P/E ratio for comparable medical device companies is about 22x, and the current S&P 500 P/E ratio is about 23x. At $20/ share, UTMD's resulting fully-diluted enterprise value would be less than 10 times trailing EBITDA.'' Investors are cautioned that this press release contains forward looking statements and that actual results may differ from those projected. Risks factors that could cause results to differ materially from those projected include market acceptance of new and/or competitive products, timing of regulatory approval of new products, UTMD's ability to efficiently manufacture, market, and sell its products, among other factors that have been outlined in UTMD's public disclosure filings with the SEC. The 10-K for year 2000 will be filed with the SEC by March 30, 2001 and will be available for direct access on the Internet for shareholders by linking through UTMD's website www.utahmed.com. The 2000 Annual Report to shareholders will be mailed about April 1, 2001. Utah Medical Products, Inc., with particular interest in healthcare for women and their babies, develops, manufactures, assembles and markets a broad range of disposable and reusable specialty medical devices designed for better health outcomes for patients and their care-providers. SOURCE: Utah Medical Products, Inc.